- Home
- SCNX vs COCP Comparison
SCNX vs COCP Comparison
Compare SCNX & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | COCP |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 15.3M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | SCNX | COCP |
|---|---|---|
| Price | $0.39 | $1.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.50 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 266.6K | 33.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | $347.88 | N/A |
| Revenue Next Year | $744.44 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.86 |
| 52 Week High | $3.17 | $2.19 |
Technical Indicators
Market Signals| Indicator | SCNX | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 50.02 |
| Support Level | $0.37 | $1.01 |
| Resistance Level | $0.47 | $1.11 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 17.42 | 44.50 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).